# Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer

> **NCT00005800** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 45 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** Filgrastim
- **DRUG:** Docetaxel
- **DRUG:** Doxorubicin
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT00005800
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-04
- **Primary completion:** 2006-01
- **Final completion:** 2012-05
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2012-09-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005800, "Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00005800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*